China's medical products administrator approved The United Laboratories International (HKG:3933) unit United Bio-Technology (Hengqin)'s phase 2 trial for its UBT251 injection for chronic kidney disease.
The drug exhibits effectiveness against glucagon-like peptide-1 which causes obesity, diabetes, and other factors, that ultimately also damage the kidneys, the filing said.
Shares rose 2% during Thursday's morning trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。